First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers

First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than one hundred million people since the beginning of the worldwide pandemic. In this study, data from a large hospital in central Italy was used to evaluate the impact of the first dose of the BNT162b2 mRNA vaccine on S...

Full description

Bibliographic Details
Main Authors: Luca Coppeta, Ottavia Balbi, Zaira Grattagliano, Grazia Genga Mina, Antonio Pietroiusti, Andrea Magrini, Matteo Bolcato, Marco Trabucco Aurilio
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Vaccines
Subjects:
SARS-CoV-2
healthcare workers
COVID-19
vaccine
mRNA vaccine
first dose administration
Online Access:https://www.mdpi.com/2076-393X/9/6/659

Internet

https://www.mdpi.com/2076-393X/9/6/659

Similar Items